2018 American Transplant Congress
Tocilizumab Stabilizes Renal Function in Kidney Transplant Recipients with Chronic Active Antibody Mediated Rejection (CAAMR)
Columbia University, New York.
INTRO: CAAMR after kidney transplantation (KTx) is associated with rates of allograft failure approaching 50% at 2 years from injury involving T cells, B cells,…2018 American Transplant Congress
Extended Experience Using Tocilizumab (Anti-IL6R, TCZ) for the Treatment of Chronic Antibody Mediated Rejection (CABMR)
Introduction: Disruption of the IL-6/IL-6R pathways may have benefits in treating allograft rejection. We reported our experience with anti-IL-6R (TCZ) as a treatment for CABMR…2018 American Transplant Congress
A Follow-Up Report on the Use of IVIG+Rituximab to Reduce Donor Specific Antibodies and Improve Transplant Rates in Highly-Sensitized Patients Awaiting Deceased Donor Kidney Transplantation
Medicine/Nephrology, Cedars Sinai Medical Center, Los Angeles, CA.
Introduction: Desensitization (DES) with IVIG/rituximab is associated with a reduction in donor specific antibodies (DSA), improved transplant rates and outcomes in highly-sensitized (HS) patients. We…2018 American Transplant Congress
Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients after Desenstization (DES): 3yrs Post Implementation
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA.
Introduction: The KAS aims to increase equity in organ allocation for broadly sensitized (HS) patients, especially (CPRA 99-100%). Coupling desensitization (DES) + KAS likely will…2018 American Transplant Congress
Follow Up of Patients Treated with the IgG Endopeptidase (IdeS) for Desensitization and HLA Incompatible (HLAi) Kidney Transplantation
Introduction:Donor-specific antibodies (DSAs) create an immunologic barrier to transplantation. This prevents transplantation for a significant percentage of highly-HLA sensitized patients (HS). Current desensitization therapies are…2018 American Transplant Congress
Molecular Monitoring for Kidney Allograft Injury Following HLA Incompatible Transplantation
Elevated donor derived cell free DNA (ddcfDNA) has been shown to correlate with allograft rejection following heart, lung, and kidney transplantation. We investigated whether sequential…2017 American Transplant Congress
Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced ABMR and rebound B-cell activity. Pathologic features of…2017 American Transplant Congress
Assessing the Impact of the New KAS on Transplant Rates in Highly-HLA Sensitized (HS) Patients After Desensitization (Des) 2 Years Post Implementation.
Introduction: The new KAS aims to improve access to transplantation for HS patients, specifically CPRA 99-100%. Our center has extensive experience w. DES to improve…2017 American Transplant Congress
Three Year Outcomes Following Positive Crossmatch Renal Transplantation Despite Failure to Convert to Negative Flow Crossmatch After Desensitization.
Purpose: To determine outcomes of positive crossmatch (PXM) renal transplant recipients that failed to convert to a negative flow cytometry crossmatch (FCXM) despite desensitization. Methods:…2017 American Transplant Congress
Outcomes of 100 ABO Incompatible Kidney Transplants: A Single US Center Experience.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA
IntroductionAcceptable patient and graft outcomes of ABO incompatible (ABOi) living donor kidney transplantation (LDKT) have been reported with the use of desensitization strategies. Data on…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- 11
- …
- 15
- Next Page »